Novartis

Novartis AG (NVS) (Q2FY25) – Innovation depth is broad, execution will determine the payoff

Highlights of the report

Novartis stands at a critical juncture in its patent lifecycle management, with the company facing significant challenges from impending generic competition while simultaneously demonstrating strong replacement power through new product launches.

CrispIdea equity reports provide valuable insights to investors who may be individuals and organizations involved in the world of finance and investment like private equity houses, broking firms, hedge funds, investment advisory firms, mutual funds, banks and corporations. This research report is useful for M&A, business & investment analysis to all students and researchers also.

 

CrispIdea equity reports include basic financials, strategic analysis, competitive landscape assessments, stock performance, stock analysis and future growth potential evaluation. CrispIdea utilizes a proprietary blend of fundamental and technical analysis, offering a unique perspective. Reports present clear investment recommendations (“BUY,” “HOLD,” or “SELL”).

 

Our established reputation and track record advocates that our research carries weight within the investment community. Do connect with us, if you are looking for customized research, equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.

 The Entresto situation exemplifies the broader patent cliff challenge
facing Novartis. With US sales contributing approximately $1.2 billion quarterly, each month of exclusivity loss represents roughly $400 million in revenue impact

Novartis AG In the last 3 months the stock has given a return of 9.74%, the stock price increased to $126.64 as of Sep 04, 2025, from $116.94 as of Jun 04, 2025

 Executive Summary

• CrispIdea Forecast

– Income Statement

– Balance Sheet

– Cash Flow

– Common Size Ratio Analysis

– CrispIdea Segment Forecast

• Valuation & Historical Performance

– P/E Analysis

– CrispIdea Valuation

– Peer Comparison

– Ratio Analysis

– Economic Value-Added Analysis

– Du Pont Analysis

– CrispIdea Forecast Relative to Consensus

– Consensus Momentum

– Segment Performance

– Key Developments

– M&A Deals

• Ownership

• Stock Price Performance

• Crispidea Coverage

Report details

Novartis AG (NVS) (Q2FY25) – Innovation depth is broad, execution will determine the payoff

Price

$288.00

Company Reports

Sector Reports